Showing 1391-1400 of 1697 results for "".
- Update on Risk of PML Infection Associated with Tysabri Presented at CMSC 2024https://practicalneurology.com/news/update-on-risk-of-pml-infection-associated-with-tysabri-presented-at-cmsc-2024/2470482/Promising results from the Tysabri Outread: Unified Commitment to Health (TOUCH) Prescribing Program were reported at the 2024 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC). Researchers found that, although cases of progressive multifocal leukoencephalopathy (PML) associat
- Ingrezza Treatment Associated with Sustained Improvements in Patients with Tardive Dyskinesiahttps://practicalneurology.com/news/ingrezza-treatment-associated-with-sustained-improvements-in-patients-with-tardive-dyskinesia/2470477/Results of a post hoc analysis of the KINECT-4 study showed that the majority of participants with tardive dyskinesia (TD) who completed 48 weeks of once-daily Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) treatment experienced clinically meaningful and sustained TD improvements.
- Novel Tau-Targeting Medication for Alzheimer Disease Associated with Sustained Cognitive Benefithttps://practicalneurology.com/news/novel-tau-targeting-medication-for-alzheimer-disease-associated-with-reduced-blood-nfl-improved-cognition/2470424/People diagnosed with early Alzheimer disease (AD) who were treated with the oral tau aggregation inhibitor HMTM (hydromethylthionine mesylate; TauRx Pharmaceuticals, Aberdeen, United Kingdom) showed improvements in standard cognitive and functional outcomes according to research presented at the
- Fintepla Associated with Stronger 12-Month Persistence than Valproate or Levetiracetamhttps://practicalneurology.com/news/fintepla-associated-with-stronger-12-month-persistence-than-valproate-or-levetiracetam/2470360/In a study presented at the 2023 American Epilepsy Society (AES) Annual Meeting, people with Dravet syndrome (DS) who used a treatment regimen based on Fintepla (fenfluramine; UCB, Atlanta, GA) demonstrated a stronger persistence over a 12-month period compared with those who used valproate or le
- Habitually Taking Daytime Naps Associated with Larger Total Brain Volumehttps://practicalneurology.com/news/habitually-taking-daytime-naps-associated-with-larger-total-brain-volume/2470229/According to research published in Sleep Health, people who habitually took daytime naps had brains that were larger by a volume equivalent to 2.6 to 6.5 years of aging compared to people who didn’t nap. The fi
- Nonpharmacologic Treatment May Be Effective in Improving Posttraumatic Headache Associated with Mild TBIhttps://practicalneurology.com/news/nonpharmacologic-treatment-may-be-effective-in-improving-posttraumatic-headache-associated-with-mild-tbi/2470220/Nonpharmacologic treatment was effective in improving posttraumatic headache resulting from mild traumatic brain injury (TBI) in veterans, according to a study presented at the 65th Annual Meeting of the American
- Study Links Photophobia Severity with Migraine-Associated Disability and Diminished Work Productivityhttps://practicalneurology.com/news/study-links-photophobia-severity-with-migraine-associated-disability-and-diminished-work-productivity/2470211/The results of a study presented at the 2023 Annual Scientific Meeting of the American Headache Society (AHS) established a correlation between severe photophobia and reduced work productivity, presenteeism, absenteeism, ac
- Genome Study Identifies Potential Bidirectional Association Between Alzheimer Disease and Epilepsyhttps://practicalneurology.com/news/genome-study-identifies-potential-bidirectional-association-between-alzheimer-disease-and-epilepsy/2470190/New research published in the online issue of Neurology identified a potential genetic link between Alzheimer disease (AD) and epilepsy. According to an analysis of results from this study, individuals who have a gen
- VMAT2 Inhibitor Helpful in Treating Chorea Symptoms Associated with Huntington Diseasehttps://practicalneurology.com/news/new-placeholder/2470187/Results from the phase 3 KINECT-HD study, published in The Lancet Neurology online edition and pending publication in the journal’s June 2023 print issue, suggest that the vesicular monoamine transporter 2 (VMA
- Brexpiprazole Approved by FDA To Treat Agitation Associated with Dementia Related to Alzheimer Diseasehttps://practicalneurology.com/news/brexpiprazole-approved-by-fda-to-treat-agitation-associated-with-dementia-related-to-alzheimer-disease/2470181/Brexpiprazole (Rexulti; Otsuka, Princeton, NJ; and Lundbeck LLC, Deerfield, IL), which is currently indicated for use as an adjunctive therapy to antidepressants for the treatment of major depres